SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $148M
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$148M
AUM Growth
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
85
New
Increased
Reduced
Closed

Top Buys

1 +$62.7M
2 +$7.13M
3 +$6.02M
4
RVMD icon
Revolution Medicines
RVMD
+$4.31M
5
TERN
Terns Pharmaceuticals
TERN
+$3.01M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CGON icon
1
CG Oncology
CGON
$6.36B
$62.9M 42.57%
+1,515,151
COGT icon
2
Cogent Biosciences
COGT
$5.9B
$7.6M 5.15%
+214,099
SLNO icon
3
Soleno Therapeutics
SLNO
$2.76B
$6.02M 4.08%
+130,079
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$5.27M 3.57%
+130,413
RVMD icon
5
Revolution Medicines
RVMD
$31B
$5.24M 3.55%
+65,800
LQDA icon
6
Liquidia Corp
LQDA
$5.03B
$3.15M 2.13%
+91,267
CMPX icon
7
Compass Therapeutics
CMPX
$337M
$3.05M 2.07%
+568,747
EXEL icon
8
Exelixis
EXEL
$12.4B
$3.01M 2.03%
+68,569
ASMB icon
9
Assembly Biosciences
ASMB
$490M
$2.51M 1.7%
+73,762
AXSM icon
10
Axsome Therapeutics
AXSM
$11.5B
$2.37M 1.6%
+12,955
TYRA icon
11
Tyra Biosciences
TYRA
$2.07B
$2.09M 1.42%
+79,560
TNGX icon
12
Tango Therapeutics
TNGX
$3.39B
$1.91M 1.29%
+215,172
ABVX
13
Abivax
ABVX
$9.63B
$1.82M 1.23%
+13,499
XNCR icon
14
Xencor
XNCR
$922M
$1.68M 1.14%
+109,554
ELVN icon
15
Enliven Therapeutics
ELVN
$2.58B
$1.54M 1.04%
+99,953
PHVS icon
16
Pharvaris
PHVS
$2.04B
$1.54M 1.04%
+55,342
MLYS icon
17
Mineralys Therapeutics
MLYS
$2.41B
$1.53M 1.03%
+42,025
BLTE
18
Belite Bio
BLTE
$6.22B
$1.47M 0.99%
+9,161
DYN icon
19
Dyne Therapeutics
DYN
$3.04B
$1.37M 0.93%
+70,180
NUVL icon
20
Nuvalent
NUVL
$8.1B
$1.27M 0.86%
+12,601
ASND icon
21
Ascendis Pharma A/S
ASND
$14.7B
$1.21M 0.82%
+5,670
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$1.17M 0.8%
+82,500
PCVX icon
23
Vaxcyte
PCVX
$7.8B
$1.17M 0.79%
+25,365
AVTX icon
24
Avalo Therapeutics
AVTX
$1.04B
$1.15M 0.78%
+63,343
IKT icon
25
Inhibikase Therapeutics
IKT
$254M
$1.09M 0.74%
+533,648